Drug intelligence / Profile preview

leucovorin + fluorouracil + irinotecan + oxaliplatin + gemcitabine + nab-paclitaxel

Development stage: Unknown
Lead developer: Sahlgrenska University Hospital
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

This entry refers to the neoadjuvant chemotherapy (NAT) regimens evaluated in a Phase III clinical trial (NCT05133011) conducted by Sahlgrenska University Hospital for patients with borderline and locally advanced pancreatic cancer. The trial compares standard versus prolonged durations of either the mFOLFIRINOX regimen (comprising leucovorin, fluorouracil, irinotecan, and oxaliplatin) or the gemcitabine plus nab-paclitaxel (GnP) regimen. These treatments are administered prior to surgical resection to improve overall survival and resection rates. mFOLFIRINOX works through a combination of DNA alkylation, thymidylate synthase inhibition, and topoisomerase I inhibition, while GnP utilizes an antimetabolite and a microtubule-stabilizing agent to disrupt cancer cell division and induce apoptosis.

Other names: mFOLFIRINOX or gemcitabine-nab-paclitaxelNAT for pancreatic cancer (Sahlgrenska)mFOLFIRINOXGnPgemcitabine-nab-paclitaxel

Targets

RNR (Ribonucleotide reductase)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on leucovorin + fluorouracil + irinotecan + oxaliplatin + gemcitabine + nab-paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on leucovorin + fluorouracil + irinotecan + oxaliplatin + gemcitabine + nab-paclitaxel.

Explore the full profile